(Sharecast News) - US biotech firm Amgen said on Tuesday that it has bought Dark Blue Therapeutics, a UK biotechnology company specialising in cancer treatments, for up to $840m.
Amgen said that University of Oxford spinout Dark Blue is advancing "first-in-class, small molecule-targeted protein degraders" for oncology.

The deal adds...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE